-
U.S. Policies Strain Life Sciences Startups
A prominent biotech investor warns that current U.S. policies are creating challenges for life sciences startups. Johannes Fruehauf, a partner at VC firm Mission BioCatpial, says that these policies are leading to increased operational costs and regulatory hurdles. The investor predicts further disruptions in the sector if these issues are not addressed. Startups face difficulties…
-
Hospitals Face Financial Strain This Summer
Hospitals are experiencing financial challenges as summer begins. According to Kaufman Hall’s “National Hospital Flash Report,” operating margins have narrowed, outpatient revenues have decreased, and expenses, especially for prescription drugs, have risen. The report, based on data from over 1,300 hospitals, highlights a decline in patient volumes. These factors contribute to the financial pressure hospitals…
-
Treatment.com AI Acquires Rocket Doctor
Treatment.com AI has acquired Rocket Doctor, a virtual care platform, to enhance its AI-powered clinical intelligence capabilities. This strategic move aims to integrate advanced AI with a successful virtual healthcare delivery system. Rocket Doctor has shown significant growth, with a 112% increase in patient volume in Alberta over the past year, serving over 36,000 patients…
-
Federal Cuts Threaten Workplace Mental Health
The National Institute for Occupational Safety and Health (NIOSH) faces severe budget cuts and staff reductions under the Trump administration, jeopardizing its efforts to address workplace mental health. NIOSH has been pivotal in initiatives to reduce suicide rates among construction workers and combat burnout in healthcare workers. Despite some staff reinstatements after congressional pushback, the…
-
FDA Layoffs Slow Overseas Drug Inspections
The FDA’s recent layoffs are causing delays in the inspection of overseas drug manufacturers. This slowdown raises concerns about medication safety. ProPublica reported on July 7 that the FDA has let go of dozens of individuals responsible for coordinating complex inspections abroad. Although some staff have been rehired, the disruption continues to affect the inspection…
-
Plus Therapeutics Gains FDA Approval for Key Dose Optimization Trial
Plus Therapeutics has received FDA approval to start the ReSPECT-LM dose optimization trial for its drug, REYOBIQ™, aimed at treating leptomeningeal metastases. The trial’s primary goal is to establish the optimal dosing schedule for a future registrational trial. This new study builds on the recommended Phase 2 dose identified in a completed Phase 1 trial….
